There's another game of musical chairs in biotech today. NPS Pharmaceuticals President and CEO Tony Coles is moving to take the reins at Onyx Pharmaceuticals. Onyx CEO Hollings Renton had announced plans to retire last October. He steps out officially at the end of March. NPS COO Francois Nader, meanwhile, is stepping up to the Coles' position. Nader joined NPS in 2006 and was promoted to COO last year.
- see this release [1]
- read the AFX report [2]
ALSO: Richard Eno was named CEO of Metabolix. Release [3]
Related Articles:
NPS pockets $30M, parts ways with AstraZeneca. Report [4]
Analyst puts NPS Pharma under microscope. Report [5]
NPS sells drug rights. Report [6]
NPS halves workforce in restructuring. Report [7]
Links:
[1] http://www.fiercebiotech.com/press-releases/nps-pharmaceuticals-announces-senior-management-changes-0
[2] http://money.cnn.com/news/newsfeeds/articles/newstex/AFX-0013-23294837.htm
[3] http://www.fiercebiotech.com/press-releases/metabolix-names-richard-p-eno-president-and-chief-executive-officer
[4] http://www.fiercebiotech.com/story/nps-pockets-30m-parts-ways-astrazeneca/2007-10-09?utm_medium=rss&utm_source=rss
[5] http://www.fiercebiotech.com/story/analyst-puts-nps-pharma-under-microscope/2007-08-07
[6] http://www.fiercebiotech.com/story/also-noted-nps-sells-drug-rights-pharmacopeia-snares-milestone-novartis-submits-galvus-protoco
[7] http://www.fiercebiotech.com/story/nps-halves-workforce-in-restructuring/2006-06-13